



S5 Fig. Comparisons of overall survival according to secondary cytoreductive surgery (CRS). (A) All patients. (B) *BRCA* mutation group. (C) *BRCA* wild-type group. (D) Combinations of secondary CRS and *BRCA1/2* mutational status.